Thrombolytic Agents: Nanocarriers in Targeted Release
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.)...
Enregistré dans:
Auteurs principaux: | Minghua Shen, Yujiao Wang, Fan Hu, Linwen Lv, Kui Chen, Gengmei Xing |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f76ee979d4a648bc935a5093c0960f3a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: What can we learn from the literature
par: Shiqi Guo, et autres
Publié: (2021) -
Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies
par: Alkaff SA, et autres
Publié: (2020) -
Extracellular Vesicles – Advanced Nanocarriers in Cancer Therapy: Progress and Achievements
par: Huyan T, et autres
Publié: (2020) -
Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective
par: Zhang J, et autres
Publié: (2021) -
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
par: Cova E, et autres
Publié: (2019)